Disclosed herein are inclusion complexes comprising vilazodone or a pharmaceutically acceptable salt thereof and an inclusion material, compositions and pharmaceutical formulations comprising the inclusion complexes, and methods for preparing the inclusion complexes, compositions or pharmaceutical formulations.

Disclosed herein are inclusion complexes comprising vilazodone or a pharmaceutically acceptable salt thereof and an inclusion material, compositions and pharmaceutical formulations comprising the inclusion complexes, and methods for preparing the inclusion complexes, compositions or pharmaceutical formulations.

A pharmaceutical composition comprising a GHRH molecule or a pharmaceutically acceptable salt thereof is described, as well as uses thereof and a kit for preparing such a pharmaceutical composition. In an embodiment, GHRH molecule or pharmaceutically acceptable salt thereof is trans-3-hexenoyl-GHRH.sub.(1-44)-NH.sub.2 or a pharmaceutically acceptable salt thereof. In an embodiment, a pharmaceutical composition comprising about 1.3 to about 1.5 mg of a GHRH molecule such as trans-3-hexenoyl-GHRH.sub.(1-44)-NH.sub.2 at a concentration of about 3.5 mg/mL or more, as well as uses thereof and a kit for preparing such a pharmaceutical composition, are described. Uses of such a pharmaceutical composition to obtain plasmatic levels of e.g., trans-3-hexenoyl-GHRH.sub.1-44)-NH.sub.2 that are bioequivalent to administration of 2 mg of trans-3-hexenoyl-GHRH.sub.(1-44)-NH.sub.2 at a concentration of 1 mg/mL in a subject are also described.

A pharmaceutical composition comprising a GHRH molecule or a pharmaceutically acceptable salt thereof is described, as well as uses thereof and a kit for preparing such a pharmaceutical composition. In an embodiment, GHRH molecule or pharmaceutically acceptable salt thereof is trans-3-hexenoyl-GHRH.sub.(1-44)-NH.sub.2 or a pharmaceutically acceptable salt thereof. In an embodiment, a pharmaceutical composition comprising about 1.3 to about 1.5 mg of a GHRH molecule such as trans-3-hexenoyl-GHRH.sub.(1-44)-NH.sub.2 at a concentration of about 3.5 mg/mL or more, as well as uses thereof and a kit for preparing such a pharmaceutical composition, are described. Uses of such a pharmaceutical composition to obtain plasmatic levels of e.g., trans-3-hexenoyl-GHRH.sub.1-44)-NH.sub.2 that are bioequivalent to administration of 2 mg of trans-3-hexenoyl-GHRH.sub.(1-44)-NH.sub.2 at a concentration of 1 mg/mL in a subject are also described.

Provided are solid self-emulsifying Cannabis plant extract formulations, methods for their preparation and uses thereof.

Provided are solid self-emulsifying Cannabis plant extract formulations, methods for their preparation and uses thereof.

The present invention is directed to an injectable pharmaceutical composition comprising (a) ursodeoxycholic acid and (b) sulfobutylether-β-cyclodextrin. Such compositions exhibit unexpected solubility and stability of ursodeoxycholic acid permitting therapeutic dosages of the ursodeoxycholic acid to be administered without the use of high amounts of strong bases that are present in an amount stoichiometrically equivalent to the ursodeoxycholic acid. The present invention is directed to an injectable pharmaceutical composition comprising (a) ursodeoxycholic acid and (b) sulfobutylether-β-cyclodextrin. Such compositions exhibit unexpected solubility and stability of ursodeoxycholic acid permitting therapeutic dosages of the ursodeoxycholic acid to be administered without the use of high amounts of strong bases that are present in an amount stoichiometrically equivalent to the ursodeoxycholic acid.

The present invention is directed to an injectable pharmaceutical composition comprising (a) ursodeoxycholic acid and (b) sulfobutylether-β-cyclodextrin. Such compositions exhibit unexpected solubility and stability of ursodeoxycholic acid permitting therapeutic dosages of the ursodeoxycholic acid to be administered without the use of high amounts of strong bases that are present in an amount stoichiometrically equivalent to the ursodeoxycholic acid. The present invention is directed to an injectable pharmaceutical composition comprising (a) ursodeoxycholic acid and (b) sulfobutylether-β-cyclodextrin. Such compositions exhibit unexpected solubility and stability of ursodeoxycholic acid permitting therapeutic dosages of the ursodeoxycholic acid to be administered without the use of high amounts of strong bases that are present in an amount stoichiometrically equivalent to the ursodeoxycholic acid.

Dry powder formulations for pulmonary and/or intranasal drug delivery, delivery systems, and methods of making and using thereof have been developed. The dry powder formulation contains particles containing a retinoid and/or a retinoid derivative, such as tamibarotene; and a β-cyclodextrin and/or a β-cyclodextrin derivative. The dry powder formulation allows for improved drug adsorption and bioavailability in vivo. The particles of the dry powder formulation have favorable aerodynamic properties for deposition and retention in the lower and/or upper respiratory tract(s). The dry powder formulation can be prepared using spray-drying or spray-freeze-drying. Inhalation, intratracheal administration, and/or intranasal administration of the dry powder formulation can deliver to a subject an effective amount of the retinoid and/or retinoid derivative to prevent, treat, or ameliorate symptom(s) associated with a respiratory viral infection in the subject.

Dry powder formulations for pulmonary and/or intranasal drug delivery, delivery systems, and methods of making and using thereof have been developed. The dry powder formulation contains particles containing a retinoid and/or a retinoid derivative, such as tamibarotene; and a β-cyclodextrin and/or a β-cyclodextrin derivative. The dry powder formulation allows for improved drug adsorption and bioavailability in vivo. The particles of the dry powder formulation have favorable aerodynamic properties for deposition and retention in the lower and/or upper respiratory tract(s). The dry powder formulation can be prepared using spray-drying or spray-freeze-drying. Inhalation, intratracheal administration, and/or intranasal administration of the dry powder formulation can deliver to a subject an effective amount of the retinoid and/or retinoid derivative to prevent, treat, or ameliorate symptom(s) associated with a respiratory viral infection in the subject.